Spanish Ministerio de Ciencia e Innovacion (MCIN)/Agencia Estatal de Investigacion (AEI) [PID2019-108489RB-I00]; European Regional Development Fund ('A way to build Europe'); Fundacio la Marato TV3 [202033]; Progeria Research Foundation (PRF) [PRF 2019-77]; Asociacion Progeria Alexandra Peraut; PRF; Swedish Research Council; Comunidad Autonoma de Madrid [2017-T1/BMD5247]; Instituto de Salud Carlos III; Pro-CNIC Foundation; MCIN/AEI [CEX2020-001041-S]; Center for Innovative Medicine
第一作者单位:[1]Ctr Nacl Invest Cardiovasc Carlos III CNIC, New Mech Atherosclerosis Program, Madrid, Spain
通讯作者:
通讯机构:[1]Ctr Nacl Invest Cardiovasc Carlos III CNIC, New Mech Atherosclerosis Program, Madrid, Spain[4]CIBER Enfermedades Cardiovasc CIBERCV, Madrid, Spain[*1]CNIC, Melchor Fernandez Almagro 3, Madrid 28029, Spain
推荐引用方式(GB/T 7714):
Benedicto Ignacio,Chen Xue,Bergo Martin O.,et al.Progeria: a perspective on potential drug targets and treatment strategies[J].EXPERT OPINION ON THERAPEUTIC TARGETS.2022,26(5):393-399.doi:10.1080/14728222.2022.2078699.
APA:
Benedicto, Ignacio,Chen, Xue,Bergo, Martin O.&Andres, Vicente.(2022).Progeria: a perspective on potential drug targets and treatment strategies.EXPERT OPINION ON THERAPEUTIC TARGETS,26,(5)
MLA:
Benedicto, Ignacio,et al."Progeria: a perspective on potential drug targets and treatment strategies".EXPERT OPINION ON THERAPEUTIC TARGETS 26..5(2022):393-399